Drug Trial Radar · NCT07180771
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Feb 2026
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).
Conditions
- Peripheral T Cell Lymphoma
Interventions
BR101801Drug
Patients will receive 200mg capsules (100mg+100mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate (ORR) (CR + PR) assessed by a blinded independent reviewer at the central lab according to the 2014 Lugano criteriaTime frame: Up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.